Last reviewed · How we verify
NCT05477979
The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
trial testing Exposure: psychological stress status in Lung Cancer in 750 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Second Xiangya Hospital of Central South University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 750 |
| Start date | 1 June 2020 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Exposure: psychological stress status
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Psychological Stress — all drugs for Psychological Stress →
- Immune Checkpoint Inhibitors — all drugs for Immune Checkpoint Inhibitors →
- Cancer, Treatment-Related — all drugs for Cancer, Treatment-Related →
Sponsor
Second Xiangya Hospital of Central South University
Who can join
18 and older, any sex, with Lung Cancer or Psychological Stress. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is the prospective, observational cohort study (STRESS-LUNG) to explore the associations of psychological stress with progression, efficacy of immune checkpoint inhibitors (ICIs) and prognosis of Lung Cancer. The participants including the patients diagnosed with advanced non-small-cell lung cancer (NSCLC) who received the first-line therapy or neoadjuvant therapy of ICIs; patients diagnosed with advanced small-cell lung cancer (SCLC) receiving the first-line therapy ICIs; patients diagnosed with early small-cell lung cancer (SCLC) receiving surgery.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer.
Zeng Y, Hu CH, Li YZ, Zhou JS, et al · · 2024 · cited 99× · PMID 38740994 · DOI 10.1038/s41591-024-02929-4 -
A narrative review from gut to lungs: non-small cell lung cancer and the gastrointestinal microbiome.
Shah H, Ng TL. · · 2023 · cited 17× · PMID 37197624 · DOI 10.21037/tlcr-22-595 -
Non-pharmaceutical interventions to optimize cancer immunotherapy.
Boesch M, Baty F, Rassouli F, Kowatsch T, et al · · 2023 · cited 8× · PMID 37791231 · DOI 10.1080/2162402x.2023.2255459 -
Immune checkpoint blockade in cancer: current insights and future horizons.
Saman H, Makni-Maalej K, El-Ella DMA, Al-Tamimi MY, et al · · 2026 · PMID 41483376 · DOI 10.1007/s12672-025-04361-7 -
Emotional distress: the hidden barrier to immunotherapy success in advanced non-small cell lung cancer.
Zhang S, Wang S, Arter ZL. · · 2025 · PMID 40535064 · DOI 10.21037/tlcr-2025-31
Verify or expand the search:
- PubMed search for NCT05477979
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exposure: psychological stress status
Trials testing the same drug.
- NCT06964503 — Impact of Psychological Stress on Treatment Response and Prognosis in Lung Cancer Patients · not yet recruiting
- NCT06690645 — The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer · recruiting
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Second Xiangya Hospital of Central South University trials
Trials by the same sponsor.
- NCT07278947 — ACT-based Parenting Program for Caregivers of Children With Hearing Loss Post-cochlear: A Pilot Randomised Controlled Tr · NA · not yet recruiting
- NCT07460336 — Effects of Cofrogliptin on Beta-Cell Function in LADA Patients · NA · not yet recruiting
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07343154 — Multimodal Brain Function in Migraine Patients With Patent Foramen Ovale · not yet recruiting
- NCT07338487 — A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Canc · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05477979 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Xiangya Hospital of Central South University
- Last refreshed: 25 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05477979.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing